Pharmacokinetics of 1-methyl-L-tryptophan after single and repeated subcutaneous application in a porcine model

Experimental Animals

Volumn 65, Issue 2, 2016, Pages 147-155

  Wirthgen, Elisa ^a   Kanitz, Ellen ^a   Tuchscherer, Margret ^a   Tuchscherer, Armin ^a   Domanska, Grazyna ^b   Weitschies, Werner ^b   Seidlitz, Anne ^b   Scheuch, Eberhard ^b   Otten, Winfried ^a  

^a LEIBNIZ INSTITUTE FOR FARM ANIMAL BIOLOGY FBN   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

3 dioxygenase; Indoleamine 2; Methyltryptophan; Pharmacokinetics; Pig; Tryptophan

Indexed keywords

INDOXIMOD; N METHYLTRYPTOPHAN; 1-METHYLTRYPTOPHAN; ENZYME INHIBITOR; INDOLEAMINE 2,3 DIOXYGENASE; TRYPTOPHAN;

AMYGDALA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CALIBRATION; CONTROLLED STUDY; ELECTROSPRAY; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; HYPOTHALAMUS; JUGULAR VEIN; KINETICS; LIMIT OF QUANTITATION; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PIG; PREFRONTAL CORTEX; PROTEIN EXPRESSION; STEADY STATE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; METABOLISM; SUBCUTANEOUS DRUG ADMINISTRATION; TIME FACTOR; TISSUE DISTRIBUTION;

ANIMALS; ENZYME INHIBITORS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INJECTIONS, SUBCUTANEOUS; MODELS, ANIMAL; SWINE; TIME FACTORS; TISSUE DISTRIBUTION; TRYPTOPHAN;

EID: 84969581242     PISSN: 13411357     EISSN: None     Source Type: Journal    
DOI: 10.1538/expanim.15-0096     Document Type: Article

References (37)

1. Bendixen, E., Danielsen, M., Larsen, K., and Bendixen, C. 2010. Advances in porcine genomics and proteomics - a toolbox for developing the pig as a model organism for molecular biomedical research. Brief. Funct. Genomics 9: 208-219
2. Cady, S.G. and Sono, M. 1991. 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch. Biochem. Biophys. 291: 326-333
3. Criado, G., Simelyte, E., Inglis, J.J., Essex, D., and Williams, R.O. 2009. Indoleamine 2,3 dioxygenase-mediated tryptophan catabolism regulates accumulation of Th1/Th17 cells in the joint in collagen-induced arthritis. Arthritis Rheum. 60: 1342-1351
4. Eder, K., Nonn, H., Kluge, H., and Peganova, S. 2003. Tryptophan requirement of growing pigs at various body weights. J. Anim. Physiol. Anim. Nutr. (Berl.) 87: 336-346
5. European Medicine Agency (EMA). 2012. Guideline on bioanalytical method validation (EMEA/CHMP/ EWP/192217/2009 Rev.1 Corr.*).
6. Felix, B., Leger, M.E., Albe-Fessard, D., Marcilloux, J.C., Rampin, O., and Laplace, J.P. 1999. Stereotaxic atlas of the pig brain. Brain Res. Bull. 49: 1-137
7. Food and Drug Administration (FDA). 2013. Guidance for Industry. Bioanalytical Method Validation: Analytical methods validation.
8. Gonzalez, A., Varo, N., Alegre, E., Diaz, A., and Melero, I. 2008. Immunosuppression routed via the kynurenine pathway: a biochemical and pathophysiologic approach. Adv. Clin. Chem. 45: 155-197
9. Health USNIo. https://www.clinicaltrials.gov/ct2/results?term=1-methyl-D-Tryptophan&Search=Search date of access: 16.09.2015.
10. Health USNIo. https://www.clinicaltrials.gov/ct2/show/results/NCT01042535?term=1-methyl-D-Tryptophan&rank=1§=Xb70156 date of access: 16.09.2015.
11. Hou, D.Y., Muller, A.J., Sharma, M.D., DuHadaway, J., Ba-nerjee, T., Johnson, M., Mellor, A.L., Prendergast, G.C., and Munn, D.H. 2007. Inhibition of indoleamine 2,3-dioxygen-ase in dendritic cells by stereoisomers of 1-methyl-trypto-phan correlates with antitumor responses. Cancer Res. 67: 792-801
12. Huttunen, R., Syrjanen, J., Aittoniemi, J., Oja, S.S., Raitala, A., Laine, J., Pertovaara, M., Vuento, R., Huhtala, H., and Hurme, M. 2010. High activity of indoleamine 2,3 dioxy-genase enzyme predicts disease severity and case fatality in bacteremic patients. Shock 33: 149-154
13. Jia, L., Wong, H., Wang, Y., Garza, M., and Weitman, S.D. 2003. Carbendazim: disposition, cellular permeability, metabolite identification, and pharmacokinetic comparison with its nanoparticle. J. Pharm. Sci. 92: 161-172
14. Jia, L., Schweikart, K., Tomaszewski, J., Page, J.G., Noker, P.E., Buhrow, S.A., Reid, J.M., Ames, M.M., and Munn, H. 2008. Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. FoodChem. Toxicol. 46: 203-211
15. Jung, I.D., Lee, M.G., Chang, J.H., Lee, J.S., Jeong, Y.I., Lee, C.M., Park, W.S., Han, J., Seo, S.K., Lee, S.Y., and Park, Y.M. 2009. Blockade of indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock. J. Immunol. 182: 3146-3154
16. Karunakaran, S., Umapathy, N.S., Thangaraju, M., Hat-anaka, T., Itagaki, S., Munn, D.H., Prasad, P.D., and Ga-napathy, V. 2008. Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy. Biochem. J. 414: 343-355
17. Kiank, C., Zeden, J.P., Drude, S., Domanska, G., Fusch, G., Otten, W., and Schuett, C. 2010. Psychological stress-induced, IDO1-dependent tryptophan catabolism: implications on immunosuppression in mice and humans. PLoS ONE 5: e11825
18. Li, A.P. 2007. In vitro evaluation of metabolic drug-drug interactions: concepts and practice. pp. 1-30. In: Drug-drug interaction in pharmaceutical development (Li, A.P. ed.), Wiley, Hoboken.
19. Linderkamp, O., Berg, D., Betke, K., Koferl, F., Kriegel, H., and Riegel, K.P. 1980. Blood volume and hematocrit in various organs in newborn piglets. Pediatr. Res. 14: 1324-1327
20. Liu, X., Newton, R.C., Friedman, S.M., and Scherle, P.A. 2009. Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. Curr. Cancer Drug Targets 9: 938-952
21. Lob, S., Konigsrainer, A., Zieker, D., Brucher, B.L., Ram-mensee, H.G., Opelz, G., and Terness, P. 2009. IDO1 and IDO2 are expressed in human tumors: levobut not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol. Immunother. 58: 153-157
22. Lob, S., Konigsrainer, A., Schafer, R., Rammensee, H.G., Opelz, G., and Terness, P. 2008. Levobut not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 111: 2152-2154
23. Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275
24. Martinez, M.N. 2011. Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems. AAPS J. 13: 632-649
25. Metges, C.C., Lang, I.S., Hennig, U., Brussow, K.P., Kanitz, Tuchscherer M., Schneider, F., Weitzel, J.M., Steinhoff-Ooster, A., Sauerwein, H., Bellmann, O., Niirnberg, G., Rehfeldt, C., and Otten, W. 2012. Intrauterine growth retarded progeny of pregnant sows fed high protein:low carbohydrate diet is related to metabolic energy deficit. PLoS ONE 7: e31390
26. Meurens, F., Summerfield, A., Nauwynck, H., Saif, L., and Gerdts, V. 2012. The pig: a model for human infectious diseases. Trends Microbiol. 20: 50-57
27. Muller, A.J., DuHadaway, J.B., Donover, P.S., Sutanto-Ward, E., and Prendergast, G.C. 2005. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11: 312-319
28. Munn, D.H., Zhou, M., Attwood, J.T., Bondarev, I., Conway, S.J., Marshall, B., Brown, C., and Mellor, A.L. 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281: 1191-1193
29. Rodriguez, H. and Kunavongkrit, A. 1983. Chronical venous catheterization for frequent blood sampling in unrestrained pigs. Acta Vet. Scand. 24: 318-320
30. Roth, W.J., Kissinger, C.B., McCain, R.R., Cooper, B.R., Marchant-Forde, J.N., Vreeman, R.C., Hannou, S., and Knipp, G.T. 2013. Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing. AAPS J. 15: 763-774
31. Talbert, A.M., Tranter, G.E., Holmes, E., and Francis, P.L. 2002. Determination of drug-plasma protein binding kinetics and equilibria by chromatographic profiling: exemplification of the method using L-tryptophan and albumin. Anal. Chem. 74: 446-452
32. Takikawa, O. 2005. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. Biochem. Biophys. Res. Commun. 338: 12-19
33. Uyttenhove, C., Pilotte, L., Theate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., and Van den Eynde, B.J. 2003. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9: 1269-1274
34. Wirthgen, E., Tuchscherer, M., Otten, W., Domanska, G., Wollenhaupt, K., Tuchscherer, A., and Kanitz, E. 2014. Activation of indoleamine 2,3-dioxygenase by LPS in a porcine model. Innate Immun. 20: 30-39
35. Yang, H.J., Yen, M.C., Lin, C.C., Lin, C.M., Chen, Y.L., Weng, T.Y., Huang, T.T., Wu, C.L., and Lai, M.D. 2010. A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity. Exp. Biol. Med. (Maywood) 235: 869-876
36. Yang, J. and Hage, D.S. 1997. Effect of mobile phase composition on the binding kinetics of chiral solutes on a protein-based high-performance liquid chromatography column: interactions of D-and L-tryptophan with immobilized human serum albumin. J. Chromatogr. A 766: 15-25
37. Zuidema, J., Kadir, F., Titulaer, H.A.C., and Oussoren, C. 1994. Release and absorption rates of intramuscularly and subcutaneously injected pharmaceuticals. Int. J. Pharm. 105: 189-207